Fig. 2From: Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patientsA The mean LogMAR BCVA values from baseline visit to week 48 visit for the patients treated with brolucizumab and aflibercept. B The mean CMT values from baseline to week 48 for the patients treated with brolucizumab and afliberceptBack to article page